Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

550.56 +5.03 (+0.92%)
Streaming Delayed Price Updated: 9:32 AM EDT, Jul 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
52 53 Next >
14 Analysts Assess Regeneron Pharmaceuticals: What You Need To Know
Via Benzinga
Price Over Earnings Overview: Regeneron Pharmaceuticals
Via Benzinga
It's Almost 2024: 3 Top Stocks to Buy Before the New Year
You can pick these players up for a great price right now. 
Via The Motley Fool
AI Meets Biotech: 3 Top Stocks Transforming Medical Science
The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology. 
Via InvestorPlace
Topics Artificial Intelligence
3 Stocks to Buy Before 2024 That Can Set You Up For Life
These stocks are still relatively cheap, but don't expect them to stay that way for long. 
Via The Motley Fool
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
Via Benzinga
11 Analysts Have This to Say About Regeneron Pharmaceuticals
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today
Via Benzinga
How Is The Market Feeling About Regeneron Pharmaceuticals?
Via Benzinga
Reasonable growth and debt and a high ROIC for REGENERON PHARMACEUTICALS (NASDAQ:REGN).
Exploring REGENERON PHARMACEUTICALS (NASDAQ:REGN)'s quality characteristics. 
Via Chartmill
3 Gene-Editing Stocks With the Potential to Mint Millionaires
Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR. 
Via InvestorPlace
Biotech Is Coming Back, Can The Run Last?
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally. 
Via Talk Markets
Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
3 biotech powerhouses poised to thrive amid sector rebound
If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader. 
Via MarketBeat
Topics ETFs
Could Regeneron Pharmaceuticals Stock Help You Become a Millionaire?
Regeneron has been an excellent investment in recent years. Can that trend continue? 
Via The Motley Fool
Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise
Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach. 
Via The Motley Fool
GOOG Stock Alert: Alphabet Is Spending Money in All the Wrong Places
The company continues to buy back Alphabet stock in large quantities. As for its other equity investments, it ought to stick with the S&P 500. 
Via InvestorPlace
Topics Stocks
$1000 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Biotech And Healthcare Portfolio Playbook For December 2023/24
We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January. 
Via Talk Markets
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
Regeneron and Sanofi are partnered on Dupixent, a treatment for conditions tied to type 2 inflammation. 
Via Investor's Business Daily
Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that... 
Via Benzinga
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Regeneron Announces Investor Conference Presentation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.